Francesca Mangiola

Francesca Mangiola

Auto-generated profile, based on publicly available information

Francesca Mangiola

Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, RM, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FMFrancesca Mangiola
Francesca Mangiola
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
FFFrancesco Franceschi
Francesco Franceschi
SFSTEFANO FAGIUOLI
STEFANO FAGIUOLI
GGGiovanni Gasbarrini
Giovanni Gasbarrini
AGAntonio Gasbarrini
Antonio Gasbarrini
The hypothesis of an important role of gut microbiota in the maintenance of physiological state into the gastrointestinal (GI) system is supported by several studies that have shown a qualitative and quantitative alteration of the intestinal flora in a number of gastrointestinal and extra-gastrointestinal diseases. In the last few years, the importance of gut microbiota impairment in the etiopathogenesis of pathology such as autism, dementia and mood disorder, has been raised. The evidence of the inflammatory state alteration, highlighted in disorders such as schizophrenia, major depressive disorder and bipolar disorder, strongly recalls the microbiota alteration, highly suggesting an important role of the alteration of GI system also in neuropsychiatric disorders. Up to now, available evidences display that the impairment of gut microbiota plays a key role in the development of autism and mood disorders. The application of therapeutic modulators of gut microbiota to autism and mood disorders has been experienced only in experimental settings to date, with few but promising results. A deeper assessment of the role of gut microbiota in the development of autism spectrum disorder (ASD), as well as the advancement of the therapeutic armamentarium for the modulation of gut microbiota is warranted for a better management of ASD and mood disorders.

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
VGViviana Gerardi
Viviana Gerardi
FMFrancesca Mangiola
Francesca Mangiola
LLLoris Riccardo Lopetuso
Loris Riccardo Lopetuso
MPMarco Pizzoferrato
Marco Pizzoferrato
AGAntonio Gasbarrini
Antonio Gasbarrini
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update

7 August 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
VGViviana Gerardi
Viviana Gerardi
LLLoris Lopetuso
Loris Lopetuso
FZFabio Del Zompo
Fabio Del Zompo
FMFrancesca Mangiola
Francesca Mangiola
AGAntonio Gasbarrini
Antonio Gasbarrini
Inflammatory bowel diseases are chronic diseases affecting the gastrointestinal tract, whose major forms are represented by Crohn’s disease (CD) and ulcerative colitis (UC). Their etiology is still unclear, although several factors have been identified as major determinants for induction or relapses. Among these, the role of the “forgotten organ”, gut microbiota, has become more appreciated in recent years. The delicate symbiotic relationship between the gut microbiota and the host appears to be lost in IBD. In this perspective, several studies have been conducted to assess the role of prebiotics and probiotics in gut microbiota modulation. This is a minireview aimed to address in an easy format (simple questions-simple answers) some common issues about the theme. An update on the role of selected constituents of gut microbiota in the pathogenesis of IBD is presented together with the analysis of the efficacy of gut microbiota modulation by prebiotics and probiotics administration in the management of IBD.

26 October 2017 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
MMMarcello Maida
Marcello Maida
Fabio Salvatore MacalusoFabio Salvatore Macaluso
Fabio Salvatore Macaluso
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
FMFrancesca Mangiola
Francesca Mangiola
ESEmanuele Sinagra
Emanuele Sinagra
GSGiuseppe Scarpulla
Giuseppe Scarpulla
Colorectal cancer (CRC) is the third most common cancer in males and second in females, and the fourth most common cause of cancer death worldwide. Currently, about 60-70% of diagnosed cases in symptomatic patients are detected at an advanced stage of disease. Earlier stage detection through the use of screening strategies would allow for better outcomes in terms of reducing the disease burden. Areas covered: The aim of this paper is to review the current published evidence from literature which assesses the performance and effectiveness of different screening tests for the early detection of CRC. Expert commentary: Adequate screening strategies can reduce CRC incidence and mortality. In the last few decades, several tests have been proposed for CRC screening. To date, there is still insufficient evidence to identify which approach is definitively superior, and no screening strategy for CRC can therefore be defined as universally ideal. The best strategy would be the one that can be economically viable and to which the patient can adhere best to over time. The latest guidelines suggest colonoscopy every 10 years or annual fecal immuno-chemical test (FIT) for people with normal risk, while for individuals with high risk or hereditary syndromes specific recommendations are provided.

1 November 2018
Verified
Journal Article
Closed access
FMF. Mangiola
F. Mangiola
ANA. Nicoletti
A. Nicoletti
AGA. Gasbarrini
A. Gasbarrini
FPF. R. Ponziani
F. R. Ponziani

17 December 2019 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
ACAndrea Costantini
Andrea Costantini
PFPietro Familiari
Pietro Familiari
MCMario Costantini
Mario Costantini
RSRenato Salvador
Renato Salvador
MVMichele Valmasoni
Michele Valmasoni
GCGuido Costamagna
Guido Costamagna